Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company, established in Stockholm, Sweden in 2004. Its core business is to discover, develop, and commercialize pharmaceutical treatments for rare diseases, initially concentrating on conditions affecting the kidneys and liver. The company's portfolio features Nefecon, an oral budesonide immunosuppressant designed to treat immunoglobulin A nephropathy, an autoimmune renal disease. A leading candidate, Setanaxib, a NOX inhibitor, is currently in Phase 2b/3 trials for primary biliary cholangitis, and Phase 2 trials for squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, Calliditas develops Budenofalk 3 mg oral capsules for the management of autoimmune hepatitis.
Check out other names from the same Biotechnology industry as CALTX.ST.